CBRNE - Lung-Damaging Agents, Phosgene Treatment & Management
- Author: Joy C Crandall, DO; Chief Editor: Robert G Darling, MD, FACEP more...
Prehospital Care
No specific antidote exists for phosgene poisoning, but supportive care options are numerous.
- Rescuer safety is paramount. Little risk exists of secondary exposure or contamination from patients who have been exposed only to phosgene gas, but any patient exposed to liquid phosgene requires decontamination to protect prehospital and in-hospital care providers and resources. Knowing the ambient temperature is important. If the environment where exposure occurred is warmer than the boiling point of phosgene (47°F), then it is likely that exposure was only to the gas form, and extensive decontamination should not be required. The patient should be removed from further exposure to the gas (taken upwind of the exposure source).
- To care for patients with liquid phosgene exposure, prehospital or HAZMAT personnel should be attired in at least level B protection (full face mask with either supplied air respirator or preferably self-contained breathing apparatus (SCBA), butyl rubber gloves, chemical protective suit, chemical resistant protective overboots). NIOSH recommends this level of protection for known phosgene concentrations in excess of 1 ppm or any situation with unknown phosgene levels. Decontamination of patients exposed to liquid phosgene should start with clothing removal and bagging/tagging of contaminated apparel. Patients should use soap and water to wash their hair and all body surfaces, with care to avoid unnecessary hypothermic stress. Warm water, warm blankets, and dry uncontaminated clothing are essential. Also see CBRNE - Chemical Decontamination.
- Because of the latency of symptom onset, all patients with suspected phosgene exposure should be transported to a medical facility for evaluation.
- Priorities for care remain airway, breathing, and circulation. If patients are being treated and transported shortly after the exposure incident, it is unlikely that that they will be severely symptomatic due the latent period associated with phosgene. If the patient reports dyspnea or chest tightness, begin therapy with supplemental oxygen. Enforce rest (litter evacuation, not walking) since any exertion shortens the latent period and worsens toxicity. Keep patients calm, warm, and quiet to minimize the work of breathing.
- Any patient with ocular exposure to phosgene should begin eye flushes with copious amounts of saline or plain water for at least 15 minutes. This treatment should be started in the prehospital setting. Contact lenses should be removed.
Emergency Department Care
- Triage
- Triage is a relatively simple matter when only a few patients are involved, but in the event of a CBRNE attack or large-scale industrial accident, triage becomes much more difficult since any one medical facility would rapidly be overwhelmed by large patient volumes.
- The numbers of "worried well" who have not actually been exposed are likely to be large in any CBRNE event, but they create a particular problem for triage of phosgene exposures because the "worried well" and the "soon to be sick" who are in the latent phase before pulmonary edema may appear identical on presentation.
- Asymptomatic patients require a minimum of 6 hours of observation, and many authors recommend 12-24 hours of observation before discharge. Patients who are eligible for discharge after this observation time should be asymptomatic with a clear lung ausculatory examination, normal respiratory rate, normal oxygen saturation, and normal chest radiograph.
- While triage is always a dynamic process, this statement is particularly true for the triage of phosgene-exposed persons, who require frequent reassessment and retriage (every 1-2 h). Some authors recommend repeating vital signs and lung ausculatory examinations every 30 minutes. The first physical sign of pulmonary edema, crackles on the ausculatory examination, typically appears at half the time of the greatest symptomatic involvement (ie, a patient who develops crackles at 3 h postexposure can be expected to be severely ill at 6 h postexposure).
- Triage depends on the availability of high-level critical care and ventilators for patients with severe pulmonary edema. If the number of patients who require ventilators outstrips the number of available ventilators, then patients who present with symptomatic pulmonary edema would likely be triaged as expectant.
- When a true mass casualty situation exists, one triage scheme that has been recommended for phosgene exposed persons is as follows:
- Minimal: Asymptomatic patients - Observe, retriage every 2 hours
- Delayed: Symptoms of dyspnea without any signs on physical examination (normal vital signs, normal oxygen saturation) - Observe, retriage every hour
- Immediate (if critical care resources are available): Signs of pulmonary edema (crackles on lung ausculatory examination, vital sign abnormalities, chest radiograph infiltrate)
- Expectant: Patients with pulmonary edema accompanied by hypotension or cyanosis
- Ensure patients have been decontaminated in the prehospital setting. If patients exposed to liquid phosgene present for care before decontamination, ensure that they are decontaminated outside of the emergency department by staff members in appropriate protective equipment (level B or higher).
- Focus on airway, breathing, and circulation. For a stridorous patient who appears to have phosgene-induced laryngospasm, proceed rapidly to pharmacologically facilitated endotracheal intubation. If orotracheal intubation is impossible, be prepared for a surgical airway. Intubated patients may have copious airway secretions that require frequent suctioning. For patients not in need of emergent intubation, provide supplemental oxygen if they have symptoms of dyspnea and/or signs of tachypnea, hypoxia, or crackles on lung ausculatory examination.
- Enforce rest for all patients exposed to phosgene to minimize work of breathing since exertion shortens the latent period and worsens the clinical course.
- For patients with pulmonary edema and worsening respiratory status (hypoxemia, hypercapnia, increased work of breathing), provide airway support with positive pressure ventilation. Initially alert patients may do well with continuous positive airway pressure (CPAP) or bilevel positive airway pressure (BiPAP), but if their clinical status declines further, they may require intubation and mechanical ventilation for support. Frequently high inspired concentrations of oxygen and high positive end-expiratory pressure (PEEP) settings are required to treat the severe hypoxemia associated with phosgene-induced noncardiogenic pulmonary edema. This therapeutic measure is intended to recruit collapsed alveoli to participate in gas exchange, thereby decreasing V/Q mismatch and improving oxygenation. However, patients will require careful monitoring of cardiovascular status because high PEEP settings may depress cardiac output by decreasing venous return.
- For patients with significant wheezing or preexisting reactive airway disease and bronchospasm, treat with standard doses of inhaled bronchodilators and inhaled anticholinergic agents such as albuterol and ipratropium bromide.
- For patients with ocular exposures to phosgene, continue the irrigation begun in the prehospital setting for a total time of at least 15 minutes. Test the patient's visual acuity and perform a slit lamp examination. Topical anesthetics may be required to attenuate blepharospasm and permit an adequate examination. Stain the corneas with fluorescein to check for any corneal epithelial defects. Refer the patient to an ophthalmologist.
Consultations
- Notify the local/state health department.
- If decontamination needs surpass hospital capabilities, request help from the local hazardous materials team.
- Discuss management with the regional poison control center.
- Notify law enforcement if industrial sabotage or an intentional release of phosgene is suspected. The Federal Bureau of Investigation (FBI) is the lead agent for investigating possible terrorist actions and weapons of mass destruction events.
- Internet sources for more information include the following: Centers for Disease Control and Prevention, Chemical Emergencies; and National Response Center (for reporting chemical spills).
US Department of Labor, Occupational Safety and Health Administration. Safety and Health Topics: Phosgene. Revised October 10, 2003. Available at http://www.osha.gov/dts/chemicalsampling/data/CH_262200.html. Accessed May 27, 2009.
Sciuto AM, Clapp DL, Hess ZA, Moran TS. The temporal profile of cytokines in the bronchoalveolar lavage fluid in mice exposed to the industrial gas phosgene. Inhal Toxicol. Jun 2003;15(7):687-700. [Medline].
Qin XJ, Li YN, Liang X, Wang P, Hai CX. The dysfunction of ATPases due to impaired mitochondrial respiration in phosgene-induced pulmonary edema. Biochem Biophys Res Commun. Feb 29 2008;367(1):150-5. [Medline].
Chen HL, Hai CX, Liang X, Zhang XD, Liu R, Qin XJ. Correlation between sPLA2-IIA and phosgene-induced rat acute lung injury. Inhal Toxicol. Feb 2009;21(4):374-80. [Medline].
[Guideline] Agency for Toxic Substances and Disease Registry. Medical management guidelines for phosgene. Accessed March 29, 2006;[Full Text].
Borak J, Diller WF. Phosgene exposure: mechanisms of injury and treatment strategies. J Occup Environ Med. Feb 2001;43(2):110-9. [Medline].
Bradley BL, Unger KM. Phosgene inhalation: a case report. Tex Med. May 1982;78(5):51-3. [Medline].
Cucinell SA. Review of the toxicity of long-term phosgene exposure. Arch Environ Health. May 1974;28(5):272-5. [Medline].
Diller WF. Early diagnosis of phosgene overexposure. Toxicol Ind Health. Oct 1985;1(2):73-80. [Medline].
Diller WF. Late sequelae after phosgene poisoning: a literature review. Toxicol Ind Health. Oct 1985;1(2):129-36. [Medline].
Diller WF. Pathogenesis of phosgene poisoning. Toxicol Ind Health. Oct 1985;1(2):7-15. [Medline].
Diller WF. Therapeutic strategy in phosgene poisoning. Toxicol Ind Health. Oct 1985;1(2):93-9. [Medline].
Diller WF, Zante R. A literature review: therapy for phosgene poisoning. Toxicol Ind Health. Oct 1985;1(2):117-28. [Medline].
Everett ED, Overholt EL. Phosgene poisoning. JAMA. Jul 22 1968;205(4):243-5. [Medline].
Glass WI, Harris EA, Whitlock RM. Phosgene poisoning: case report. N Z Med J. Dec 1971;74(475):386-9. [Medline].
Guo YL, Kennedy TP, Michael JR, Sciuto AM, Ghio AJ, Adkinson NF Jr, et al. Mechanism of phosgene-induced lung toxicity: role of arachidonate mediators. J Appl Physiol. Nov 1990;69(5):1615-22. [Medline].
Karalliedde L, Wheeler H, Maclehose R. Possible immediate and long-term health effects following exposure to chemical warfare agents. Public Health. Jul 2000;114(4):238-48. [Medline].
Kennedy TP, Michael JR, Hoidal JR. Dibutyryl cAMP, aminophylline, and beta-adrenergic agonists protect against pulmonary edema caused by phosgene. J Appl Physiol. Dec 1989;67(6):2542-52. [Medline].
Lazarus AA, Devereaux A. Potential agents of chemical warfare. Worst-case scenario protection and decontamination methods. Postgrad Med. Nov 2002;112(5):133-40. [Medline].
Lim SC, Yang JY, Jang AS, Park YU, Kim YC, Choi IS, et al. Acute lung injury after phosgene inhalation. Korean J Intern Med. Jan 1996;11(1):87-92. [Medline].
Parrish JS, Bradshaw DA. Toxic inhalational injury: gas, vapor and vesicant exposure. Respir Care Clin N Am. Mar 2004;10(1):43-58. [Medline].
Peters PL. Phosgene medical information. J Ark Med Soc. Oct 1977;74(5):193-5. [Medline].
Polednak AP, Hollis DR. Mortality and causes of death among workers exposed to phosgene in 1943-45. Toxicol Ind Health. Oct 1985;1(2):137-51. [Medline].
Regan RA. Review of clinical experience in handling phosgene exposure cases. Toxicol Ind Health. Oct 1985;1(2):69-72. [Medline].
Sciuto AM, Hurt HH. Therapeutic treatments of phosgene-induced lung injury. Inhal Toxicol. Jul 2004;16(8):565-80. [Medline].
Sciuto AM, Moran TS, Narula A, Forster JS. Disruption of gas exchange in mice after exposure to the chemical threat agent phosgene. Mil Med. Sep 2001;166(9):809-14. [Medline].
Sidell FR. Triage of chemical casualties. In: Zajtchuk R, Bellamy RF, eds. Medical Aspects of Chemical and Biological Warfare. 1997:337-49.
Smart JK. History of chemical and biological warfare: an American perspective. In: Zajtchuk R, Bellamy RF, eds. Medical Aspects of Chemical and Biological Warfare. 1997;9-86.
Snyder RW, Mishel HS, Christensen GC. Pulmonary toxicity following exposure to methylene chloride and its combustion product, phosgene. Chest. Mar 1992;101(3):860-1. [Medline].
Snyder RW, Mishel HS, Christensen GC 3rd. Pulmonary toxicity following exposure to methylene chloride and its combustion product, phosgene. Chest. Dec 1992;102(6):1921. [Medline].
Urbanetti JS. Toxic inhalational injury. Medical Aspects of Chemical and Biological Warfare. 1997;247-270.
US Army Medical Research Institute of Chemical Defense. 3rd ed. Medical Management of Chemical Casualties Handbook. 1999.
Wang YT, Lee LK, Poh SC. Phosgene poisoning from a smoke grenade. Eur J Respir Dis. Feb 1987;70(2):126-8. [Medline].
Warden CR. Respiratory agents: irritant gases, riot control agents, incapacitants, and caustics. Crit Care Clin. Oct 2005;21(4):719-37, vi. [Medline].
Wells BA. Phosgene: a practitioner's viewpoint. Toxicol Ind Health. Oct 1985;1(2):81-92. [Medline].
Wyatt JP, Allister CA. Occupational phosgene poisoning: a case report and review. J Accid Emerg Med. Sep 1995;12(3):212-3. [Medline].

